MedTrace Logo

PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer

NCT03439215 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-07-19

No results posted yet for this study

Summary

This is a phase II study assessing response rate to PF-06463922 in patients with ROS1 translocation resistant to previous crizotinib therapy. Eligible patients will be treated with the study drug until disease progression, unacceptable toxicity or patient refusal. Disease assessment will be performed every 8 weeks according to RECIST criteria.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Lorlatinib

Lorlatinib is a novel small-molecule ROS1/ALK inhibitor that was optimized for robust brain penetration.

Sponsors & Collaborators

  • Clinical research technology Srl

    collaborator UNKNOWN

  • Fondazione Ricerca Traslazionale

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-13
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03439215 on ClinicalTrials.gov